Stocks analysis

AAPL vs ABBV Stock Comparison

Scores Breakdown

Metric AAPL ABBV
📈 Growth 18/30 15/30
💰 Profitability 16/20 16/20
🏦 Financial Health 18/20 12/20
💵 Valuation 14/20 12/20
⚠️ Risk (lower is better) 4/10 6/10
Overall Score 72/100 59/100

Side-by-Side Summaries

AAPL Analysis ABBV Analysis

📈 Growth & Financial Trajectory

Over eight quarters, Apple shows revenue volatility but an overall uptick: from approximately Revenues 94.93B in 2024 Q3 to about 111.18B in 2026 Q2, a gain of ~16B. Net income rose from about 21.45B to ~29.58B, though quarterly results swing with mid-cycle peaks (e.g., 2025 Q1) and pullbacks (2025 Q2) that temper a steady climb.

💰 Margins & Cash Flow

Gross margin remains robust, typically in the high-40s percent range. Operating leverage is evident as operating income stays positive even when revenues pause. Cash flow shows resilience: Net Cash Flow From Operating Activities is generally positive across quarters, with seasonal peaks; investing cash outflows are typical, while financing activity cash flows vary by quarter.

🛡️ Balance Sheet & Liquidity

Assets exceed liabilities by a wide margin, with sizable current assets and a strong equity base. Debt levels are manageable relative to cash generation, and the balance sheet demonstrates liquidity headroom to support ongoing capex and buybacks.

⚠️ Key Drivers & Risks

  • Drivers: Premium hardware and Services expansion; margin resilience amid product cycles
  • Risks: Valuation sensitivity to growth prospects; cyclicality and FX/macro headwinds

📈 Growth & Financial Trajectory

8 quarters show a largely rising topline: 2024Q1 to 2026Q1 Revenues rise from about $12.31B to $15.00B (+≈22%). Net income attributable to parent falls from ~$1.29B to ~$0.70B, though peaks around ~$1.86B in 2025Q2–Q3, with 2025Q4 at ~$1.82B. The trend is mixed: topline strength persists, but bottom-line profitability weakens into 2026Q1.

💰 Margins & Cash Flow

Gross margins remain high, broadly ~70–79%, reflecting a durable product mix. Operating leverage remains healthy as volumes expand. Net cash flow from operating activities stays robust, typically around $5.1B–$5.3B per quarter; investing activity is negative (capex/activity), and financing flows cause periodic swings.

🛡️ Balance Sheet & Liquidity

Total assets hover near the mid-to-upper hundreds of billions with liabilities that verge on or exceed assets in some periods, and equity attributable to the parent is often negative (reflecting buybacks). The firm generates solid operating cash flow that supports liquidity despite leverage. Long-term debt runs in the mid-$60B range in recent periods, with current liabilities ~$39–$44B.

⚠️ Key Drivers & Risks

  • Drivers: Robust pharma demand and a durable high-margin mix; ongoing pipeline progress.
  • Risks: Patent/regulatory pressures; elevated leverage and sensitivity to interest rates; potential valuation volatility.